23andMe Holding Co. (ME) – Globe Newswire
-
23andMe announces CEO’s intention to pursue a potential take-private
-
23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
-
23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
-
23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago
-
23andMe Launches New Genetic Reports on Common Forms of Cancer
-
23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
-
23andMe Reports Third Quarter Fiscal 2024 Financial Results
-
23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
-
23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay
-
23andMe to Report FY2024 Third Quarter Financial Results
-
23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts
-
23andMe Reports Second Quarter Fiscal 2024 Financial Results
-
23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership
-
23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
-
23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health Data
-
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
-
23andMe to Report FY2024 Second Quarter Financial Results
-
23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting
-
23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program
-
23andMe Granted New FDA Clearance to Report Additional BRCA Variants
-
23andMe Reports FY2024 First Quarter Financial Results
-
23andMe to Report FY2024 First Quarter Financial Results
-
23andMe Releases New FDA-Cleared Genetic Report on Simvastatin, a Commonly Prescribed Statin
-
23andMe Releases New Report Revealing Genetic Likelihood of Experiencing Panic Attacks
-
23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results
-
New 23andMe survey reveals nine out of ten physicians in the U.S. believe genetics play an important part of a patient’s complete health picture
-
23andMe to Report FY2023 Fourth Quarter and Full Year Financial Results
-
23andMe Releases New Report Revealing Likelihood of Developing Lupus
-
Reza Afkhami Joins 23andMe as Chief Corporate Development Officer
-
23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
-
23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
-
Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program
-
Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program
-
23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease
-
23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease
-
23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023
-
23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023
-
New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare
-
23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies
-
23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies
-
23andMe to Present at Upcoming Investor Conferences
-
23andMe to Present at Upcoming Investor Conferences
-
23andMe Reports FY2023 Third Quarter Financial Results
-
23andMe Reports FY2023 Third Quarter Financial Results
-
23andMe to Report FY2023 Third Quarter Financial Results
-
23andMe to Report FY2023 Third Quarter Financial Results
-
23andMe Survey Shows Majority of People Less Stressed About Their Health During This Holiday Season
-
23andMe Survey Shows Majority of People Less Stressed About Their Health During This Holiday Season
-
23andMe Reports FY2023 Second Quarter Financial Results
-
23andMe Reports FY2023 Second Quarter Financial Results
Back to ME Stock Lookup
